MATERIALS AND METHODS

Criteriafor Eligibility and Description of Patients
The criteria for patient eligibility were reported in detail elsewhere." '8 In brief, patients had histologic evidence of metastatic cancer with a life expectancy of at least 2 months. No chemotherapy or radiotherapy had been administered in the 6 weeks preceding treatment with rG-CSF, and radiotherapy was limited to less than 50% of the bone marrow. The type of tumor had to justify treatment with melphalan, and significant nonmalignant disease such as candiac, respiratory, renal, or hepatic dysfunction was excluded. Pretreatment hemoglobin levels were greater than 10 g/dL, polymorphonuclear cell counts greater than 1,500/giL, and platelet counts greater than 100,000/giL. Before initiation of treatment the patients gave informed consent. Table I) . The cultures were incubated in a fully humidified atmosphere of 5% CO2 in air at 37#{176}C for up to 14 days.
Properties of rG-CSF
Granulocyte-macrophage
and early erythnoid progenitor cells were grown in agan cultures prepared by adding 1 vol of doublestrength Iscove's modified Dulbecco's medium and 1 vol of FCS to 2 vol of 0.6% agan.' Gnanulocyte-macrophage progenitor cells were stimulated by the addition to each dish of (a) 500 units of purified rG-CSF (specific activity, 2 x i0 U/mg) dissolved in a volume of 0.1 mL of saline, (b) 1,500 units of purified recombinant granulocyte-macrophage colony-stimulating factor (nGM-CSF) (specific activity, Late erythroid progenitor cells (colony-forming units, erythroid; CFU-E)
were assayed in methylcellulose cultures by using 2 U/mL of rEpo.' The cultures were scored after seven days of incubation by using an inverted microscope and CFU-E identified as hemoglobinized clones of eight cells or more. 
Statistical Analysis
The t test for paired samples (one tailed) was used to compare progenitor cell numbers before and after treatment with rG-CSF. 
RESULTS
Fractionation ofCell Samples
